Ankylosing Spondylitis Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Ankylosing Spondylitis Treatment Market Trends and Insights

Growing Global Prevalence & Earlier Diagnosis

Consensus criteria for “early axial spondyloarthritis” let clinicians intervene before structural damage becomes irreversible, adding previously uncounted patients to the ankylosing spondylitis treatment market.^{[1]Source: Victoria Navarro-Compán et al., “ASAS Consensus Definition of Early Axial Spondyloarthritis,” PubMed, pubmed.ncbi.nlm.nih.gov} Ethnic-specific HLA-B27 subtypes identified in East Asian cohorts refine risk stratification and enable targeted screening. National registries in China and India are reporting higher case ascertainment as rheumatology capacity increases, magnifying demand for both first-line NSAIDs and advanced biologics. These combined shifts are expected to keep new patient starts on an upward curve through the medium term.

Expanding Reimbursement Coverage for Biologics & Biosimilars

Pharmacy benefit managers in the United States now privilege low-priced adalimumab and ustekinumab biosimilars, with several plans offering USD 0 co-pay switching incentives. Parallel moves in the European Union have lifted biosimilar uptake above 70% in certain markets, compressing net prices and broadening access. Latin American payers are adopting tiered formularies that admit two or more biosimilars per molecule, creating multi-supplier competition. Cost savings redirected toward dual IL-17 inhibitors and JAK inhibitors are enlarging the overall ankylosing spondylitis treatment market rather than merely cannibalizing existing spends. Faster market penetration of biosimilars is therefore amplifying volume growth, even as average selling prices soften.

Oral JAK-Inhibitors Improving Patient Adherence

Once-daily upadacitinib and twice-daily tofacitinib ease injection fatigue, helping sustain adherence in younger, professionally active patients. Five-year safety monitoring shows no excess overall malignancy risk versus biologic DMARDs, though vigilance for non-melanoma skin cancer remains prudent. Mechanistic breadth across multiple cytokines offers a therapeutic alternative for patients unresponsive to TNF- or IL-17-targeted agents. Early real-world evidence indicates a measurable decline in outpatient visits linked to easier oral dosing, further incentivizing payers to add JAK inhibitors to preferred tiers.

AI-Enabled MRI Scoring Speeding Clinical Trial Timelines

Machine-learning-based Berlin scoring attains 67% concordance with expert radiologists, while newer convolutional models reach AUC values of 0.96 in test datasets. Automating image reads cuts both subjectivity and labor costs, enabling smaller protocols with higher statistical power. Sponsors report that AI-enhanced endpoints have reduced imaging-related timelines by roughly six months in recent phase III programs. Regulators in the United States and Europe have begun accepting algorithm-supported readouts as secondary efficacy measures, signaling future mainstream adoption. These gains make drug development more attractive in niche inflammatory indications, indirectly expanding the therapeutic toolkit available to the ankylosing spondylitis treatment market.

High Cost of Originator Biologics

List prices for established TNF inhibitors continue to test payer budgets, prompting stricter prior authorization and step-therapy mandates. Although the U.S. Inflation Reduction Act promises relief for Medicare beneficiaries, commercial plans still negotiate rebates on a product-by-product basis. Insurers increasingly channel patients toward preferred biosimilars, but uptake remains slower in regions lacking automatic pharmacy-level substitution. In emerging economies, limited public financing forces many patients to defer biologic initiation, restricting the potential universe for the ankylosing spondylitis treatment market until broader subsidy schemes materialize.

Safety Warnings for JAK Inhibitors & Long-Term Immunosuppression

Post-marketing surveillance has highlighted cardiovascular and thrombotic events, triggering boxed warnings and targeted risk-evaluation strategies. Nevertheless, pooled real-world data from over 53,000 initiations reveal no significant rise in overall cancer rates versus biologics, except for a marginal uptick in non-melanoma skin cancers.^{[2]Source: European Alliance of Associations for Rheumatology, “New Data Reveals Insights Into Cancer and Cardiovascular Safety of JAK Inhibitors,” News-Medical, news-medical.net} Physicians now tailor JAK inhibitor use to younger, lower-risk profiles and employ periodic dermatologic screening. Regulatory agencies continue to refine labeling, which keeps a perceptual cloud over the class and slows its share-of-wallet expansion.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: Biosimilar Headwinds Meet NSAID Resurgence

TNF inhibitors retained 53.68% ankylosing spondylitis treatment market share in 2025, supported by two-decade clinical familiarity and extensive payer coverage. However, erosive price competition from eight approved adalimumab biosimilars and the expanding footprint of infliximab-dyyb are moderating revenue growth. IL-17 blockers, led by secukinumab and ixekizumab, are enlarging their patient base in biologic-naïve cohorts who value rapid entheseal pain relief. Meanwhile, dual-target bimekizumab is expected to capture early switchers by demonstrating superior radiographic control. JAK inhibitors are carving a niche among patients with prior biologic failure, offering oral convenience and broader cytokine coverage.

NSAIDs are rebounding, registering an 8.79% CAGR to 2031—the highest among all classes—after long-term cohort data confirmed that continuous celecoxib therapy retards spinal damage progression. This evidence has reinstated selective COX-2 inhibitors as quasi–disease-modifying agents rather than mere analgesics. Combined with individualized exercise regimens, etoricoxib has delivered meaningful functional gains, further broadening its uptake. Novel candidates such as anti-GM-CSF antibodies and nanomedicine formulations remain experimental but highlight the innovation pipeline poised to feed future growth in the ankylosing spondylitis treatment market.

By Route of Administration: Oral Surge Challenges Injectable Dominance

Subcutaneous formulations delivered 58.92% of 2025 revenue, reflecting patient self-administration convenience and the broadest commercial portfolio, including adalimumab, secukinumab, and newly launched bimekizumab. Prefilled starter kits and connected autoinjectors are improving dosing accuracy and adherence tracking. However, oral delivery is projected to be the fastest-growing route at a 8.99% CAGR, catalyzed by JAK inhibitor enthusiasm and payer acceptance of tablet-based chronic therapies. Clinical equivalence to biologics in ASAS40 response, combined with easier supply chain logistics, underpins this ascent.

Intravenous infusions, once the mainstay for infliximab, now serve a more specialized subset—patients experiencing injection-site reactions or needing high-dose induction. Hospitals and stand-alone infusion centers are optimizing chair time and adopting biosimilar infliximab to retain volume. Market momentum nonetheless favors modalities that minimize facility dependence, prompting manufacturers to re-engineer IV-only molecules into high-concentration subcutaneous or oral versions. Route flexibility is thus becoming a competitive differentiator in the ankylosing spondylitis treatment market.

By Distribution Channel: Specialty Digital Models Gain Ground

Hospital pharmacies captured 49.85% of overall revenue in 2025, underpinned by integrated infusion services and in-house rheumatology consults. They remain indispensable for biologic initiation, safety monitoring, and adverse-event management. Retail chains hold stable share by dispensing NSAIDs and oral small molecules but continue to cede high-complexity biologics to specialized arms.

Online and specialty pharmacies are on track for an 8.52% CAGR through 2031. Improved cold-chain orchestration, insurer-aligned copay assistance, and doorstep nurse training are boosting acceptance, particularly among working-age patients seeking discretion and convenience. Digital refill reminders and adherence analytics further differentiate these providers. As reimbursement frameworks evolve toward home-based care, e-pharmacy platforms are poised to unlock incremental value across the ankylosing spondylitis treatment market.

Geography Analysis

North America’s 40.78% contribution in 2025 underscores its role as the innovation nucleus for advanced therapeutics and digital management tools. Early FDA approvals for dual IL-17 agents and rapid biosimilar turnover exemplify a dynamic yet price-sensitive environment. Major payers now embed performance guarantees into contracts, while remote monitoring apps gain traction among high-deductible health plan enrollees. Differences in Medicare Part D formularies create state-level access disparities, influencing switching patterns and overall utilization.

Asia Pacific is forecast to deliver the highest 9.03% CAGR through 2031, anchored by China’s 0.26% disease prevalence and distinctive HLA-B27 landscape that makes 88.8% of diagnosed patients genetically predisposed. Rising middle-class insurance coverage, government-funded biosimilar programs, and an expanding network of rheumatology clinics are accelerating first-line biologic uptake. South Korea and Japan continue to operate mature reimbursement models, whereas India’s tiered hospital accreditation system is gradually unlocking infliximab and adalimumab access beyond metropolitan centers. Across Southeast Asia, tele-consult services are shortening wait times and bolstering guideline adoption.

Europe maintains a steady revenue base, aided by the region’s leadership in biosimilar policy and real-world evidence generation. Germany’s national cohort studies inform global dosing optimization, while the United Kingdom’s value-based pricing scheme incentivizes measurable functional improvements. Nationalized health systems leverage pooled purchasing power to secure attractive tender prices, promoting broad access yet compressing manufacturer margins. Central and Eastern European countries are narrowing the gap through EU structural funds dedicated to rheumatology infrastructure, paving the way for more uniform penetration of the ankylosing spondylitis treatment market.

Regulatory Landscape

Regulatory pathways for ankylosing spondylitis therapies are increasingly shaped by cross-market approvals and labeling updates for IL-17 inhibitors. In the United States, the FDA approved BIMZELX (bimekizumab-bkzx) in 2024 for active ankylosing spondylitis and non-radiographic axial spondyloarthritis, expanding the IL-17 class footprint and informing clinical sequencing. In Europe, centralized decisions via the European Commission and EMA continue to broaden options, with EC authorizations for Gobivaz in late 2025 and Gotenfia in early 2026 for severe active ankylosing spondylitis.

In China, the NMPA accepted Crusekitug (QX002N) for active AS in March 2026, signaling domestic IL-17 assets moving toward formal review and increasing competitive dynamics within the IL-17 segment.

Market Opportunities and Future Outlook

The current landscape creates opportunities to expand access and differentiation within the IL-17 and next generation immunology segments, especially where switching from TNF inhibitors is common and payers are recalibrating prices through biosimilar dynamics. China approvals and filings expand the addressable set; the NMPA accepted NDA activity around IL-17 agents such as gumokimab (AK111) in 2026, underscoring an active in-country expansion channel through approvals, licensing, and partnerships.

Beyond cytokine inhibition, the treatment toolkit is widening toward targeted synthetic and precision immune approaches for inadequate responders and for patients showing structural progression. This aligns with treat-to-target patterns and the increasing emphasis on longitudinal monitoring, where outcomes drive therapy selection.